Related Experiment Video
Updated: May 24, 2026
12:50
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
Endothelins -- clinical perspectives
Adriana Unic1, Lovorka Derek, Natasa Hodak
1Clinical Department of Laboratory Diagnostics, Dubrava University Hospital, Zagreb, Croatia. aunic@kbd.hr
Biochemia Medica
|March 17, 2012
Summary
Endothelins (ET) are potent vasoconstrictors influencing blood pressure. This review explores endothelin-1 (ET-1) physiology, its receptors (ETRA, ETRB), and roles in various diseases.
Area of Science:
- Cardiovascular Physiology
- Molecular Pharmacology
Background:
- Endothelins (ET) are peptides with potent, long-lasting vasoconstrictive effects.
- Three isoforms (ET-1, ET-2, ET-3) exist, with ET-1 being the most potent vasoconstrictor.
- Endothelin's biological effects are mediated by G-protein coupled receptors: ETRA and ETRB (ETRB1, ETRB2).
Purpose of the Study:
- To review the physiological and pathophysiological roles of endothelium-derived ET-1.
- To discuss the pharmacology of ETRA and ETRB receptors.
- To focus on ET-1's involvement in the development of pathophysiological conditions.
Main Methods:
- Literature review of physiological and pathophysiological roles of ET-1.
- Analysis of endothelin receptor pharmacology (ETRA, ETRB1, ETRB2).
- Synthesis of current understanding of ET-1 in disease development.
Main Results:
- ET-1 binding to ETRA mediates vasoconstriction, bronchoconstriction, and aldosterone secretion.
- ETRB1 activation promotes vasodilation via NO, PGI2, and EDHF.
- ETRB2 activation leads to vasoconstriction.
Conclusions:
- Endothelin-1 plays a significant role in cardiovascular regulation and disease.
- Understanding ET-1 and its receptor interactions is crucial for therapeutic development.
- Further research is needed on the newly discovered ETRC.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Acute Inflammation III: Local and Systemic Effects
Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
01:25Endocarditis II: Clinical Features of Infective Endocarditis
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:17Intracellular Signaling Affects Focal Adhesions
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...